NCT02237989

Brief Summary

The aim of this study was to evaluate symptomatic efficacy of native collagen type 2 on joint pain and function and its effects on urinary biological markers related to cartilage degeneration in patients with knee osteoarthritis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable knee-osteoarthritis

Timeline
Completed

Started Jan 2013

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

September 10, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 12, 2014

Completed
6 years until next milestone

Results Posted

Study results publicly available

September 18, 2020

Completed
Last Updated

September 18, 2020

Status Verified

September 1, 2020

Enrollment Period

11 months

First QC Date

September 10, 2014

Results QC Date

August 13, 2020

Last Update Submit

September 17, 2020

Conditions

Keywords

knee osteoarthritis, native collagen type 2, paracetamol

Outcome Measures

Primary Outcomes (1)

  • the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking)

    Post treatment comparison of VAS walking between the groups minimum score is 0, maximum score is 10. The clinic of the patient worses when the score increases.

    3 months

Secondary Outcomes (4)

  • the Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score

    3 months

  • the Change From Baseline in 20 Meters Walking Time

    3 months

  • the Change From Baseline in Short Form 36 / Bodily Pain Subgroup

    3 months

  • the Change From Baseline in Coll2-1 Levels

    3 months

Study Arms (2)

paracetamol

ACTIVE COMPARATOR

The 1st group includes 19 patients given 1500mg/day paracetamol for three months

Drug: paracetamol

native collagen type 2 + paracetamol

EXPERIMENTAL

The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months

Drug: paracetamol+native collagen type 2

Interventions

1500 mg

paracetamol

paracetamol (1500 mg) + native collagen type 2 (10mg)

native collagen type 2 + paracetamol

Eligibility Criteria

Age45 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Bakilan F, Armagan O, Ozgen M, Tascioglu F, Bolluk O, Alatas O. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016 Jun;48(2):95-101. doi: 10.5152/eurasianjmed.2015.15030.

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Acetaminophen

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Results Point of Contact

Title
Dr. Fulya Bakılan
Organization
Eskisehir Osmangazi University

Study Officials

  • Fulya Bakilan, Specialist

    Yerkoy State Hospital

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Onur Armagan, Medical Doctor

Study Record Dates

First Submitted

September 10, 2014

First Posted

September 12, 2014

Study Start

January 1, 2013

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

September 18, 2020

Results First Posted

September 18, 2020

Record last verified: 2020-09